CompletedPhase 1ACTRN12608000603314

An Open-Label, Dose Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery


Sponsor

Icon Bioscience

Enrollment

10 participants

Start Date

May 11, 2007

Study Type

Interventional

Conditions

Summary

The purpose of this study is to test the safety and tolerability of a extended duration drug delivery system for the eye.


Eligibility

Sex: Both males and femalesMin Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a steroid injection (triamcinolone acetonide) given directly into the eye to treat swelling in the central part of the retina caused by blocked blood vessels or cataract surgery. Participants must be 45 or older. People whose vision is unlikely to improve with treatment or who have recently had other eye treatments are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Intravitreal injection of extended release triamcinolone acetonide for treatment of macular edema. Each patient will receive only one injection. The first cohort of five patients will all receive th

Intravitreal injection of extended release triamcinolone acetonide for treatment of macular edema. Each patient will receive only one injection. The first cohort of five patients will all receive the 6.9 mg injection. The second cohort of five patients will receive the 13.8 mg injection.


Locations(1)

CA, United States of America

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000603314


Related Trials